NEW ORLEANS, LOUISIANA -- (MARKET WIRE) -- March 26, 2007 -- Resverlogix Corp. ("Resverlogix") (TSX: RVX), is pleased to announce that in preparation for the Investigational New Drug (IND) submission to the Food and Drug Administration (FDA) and Phase l Clinical trial the Clinical Advisory Board met in New Orleans in conjunction with the American College of Cardiology meeting. Resverlogix's lead drug candidate, RVX-208, is a first-in-class ApoA-I/HDL elevating small molecule which is undergoing IND-enabling studies and phase 1 human clinical study preparations. The excitement surrounding RVX-208 is linked to its high capacity to increase plasma ApoA-I/HDL levels by increased production of the ApoA-I protein, a biological process termed "ApoA-I enhancement".
